Responses
Emerging technologies, pharmacology and therapeutics
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
Compose a Response to This Article
Other responses
No responses have been published for this article.